$PRSC (Providence Service Corp.)

$PRSC {{ '2016-03-11T05:21:43+0000' | timeago}} • Announcement

Health risk assessment company $PRSC reported 4Q15 net income available to stockholders of $63.7MM or $4.07 per diluted share, up 803.4% versus $7.1MM or $0.45 per diluted share in 4Q14, helped by income from discontinued operations, net of tax, of $101.5MM. Consolidated revenue rose 15.4% to $424.9MM versus $368.3MM in 2014.

$MMS {{ '2018-01-16T21:43:43+0000' | timeago}} • Announcement

$MMS announced that Richard A. Montoni will retire from his role as CEO effective April 1, 2018. The Board of Directors has selected President Bruce L. Caswell to succeed Mr. Montoni as CEO.

$MMS {{ '2018-01-11T13:24:10+0000' | timeago}} • Announcement

$MMS has declared a quarterly cash dividend of $0.045 per share on its common stock. The dividend is payable on February 28, 2018, to shareholders of record on February 15, 2018.

$MD {{ '2018-01-10T15:20:12+0000' | timeago}} • Announcement

$MD announced the acquisition of Tri-Valley Neonatal Medical Group, Inc., a private neonatology physician practice based in California. This was a cash transaction and it is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed.

$LLY {{ '2018-01-08T19:33:20+0000' | timeago}} • Announcement

$LLY join hands with consumer digital health company Livongo Health to study real world behaviors of people affected with diabetes. This collaboration is expected help the diabetic people to better manage their condition.

$EBS {{ '2018-01-08T14:21:21+0000' | timeago}} • Announcement

$EBS expects total revenues to be $715-755MM for full-year 2018. Net income is expected to be $95-110MM while adjusted net income is expected to be $110-125MM. Pretax income is expected to be $120-140MM while EBITDA is expected to be $175-190MM for full-year 2018.

$EBS {{ '2018-01-08T14:21:06+0000' | timeago}} • Announcement

$EBS announced preliminary 2017 financial results. For full-year 2017, $EBS expects total revenue of $555-560MM and BioThrax sales of approx. $286MM. $EBS expects net income to be $80-84MM and adjusted net income to be $92-96MM. Cash and cash equivalents at 2017-end are expected to be approx. $180MM.

$HUM {{ '2017-12-19T15:27:46+0000' | timeago}} • Announcement

$HUM signed a definitive agreement to acquire a 40% minority interest in the Kindred at Home Division of $KND for an estimated cash consideration of approximately $800MM. Humana does not anticipate a material impact to earnings in 2017 from this pending transaction.

$KND {{ '2017-12-19T13:44:51+0000' | timeago}} • Announcement

$KND's BoD approved a definitive agreement whereby it will be acquired by a consortium of three companies: TPG Capital, Welsh, Carson, Anderson & Stowe and $HUM for about $4.1Bil in cash including the assumption or repayment of net debt. The transaction is expected to close during the summer of 2018.

$LLY {{ '2017-12-14T18:20:39+0000' | timeago}} • Announcement

$LLY join hands with diabetes management firm Rimidi to provide personalized solutions for diabetic patients who are using insulin. As per the agreement, Rimidi's diabetes management software platform will be integrated with Lilly's insulin management system which is in development.

$ESRX {{ '2017-12-14T15:34:37+0000' | timeago}} • Announcement

$ESRX's enterprise value initiative is currently estimated to cost approx. $600-650MM and to deliver cumulative savings of nearly $1.2Bil by 2021. The company's 2018 full-year guidance includes an estimated contribution of $65-75MM in expense savings affecting the Core and consolidated businesses.

$ESRX {{ '2017-12-14T15:34:20+0000' | timeago}} • Announcement

For 2018, $ESRX expects adjusted diluted EPS to be $7.67-7.87, up 9-12% from the midpoint of the updated 2017 adjusted EPS guidance range. The company expects consolidated revenue to be $99-102Bil and Core revenue to be $80.5-83Bil. Total adjusted claims for the consolidated business is expected to be $1.34-1.39Bil.

$ESRX {{ '2017-12-14T15:34:05+0000' | timeago}} • Announcement

$ESRX expects full-year 2017 total adjusted claims for its Core business to be 1.15-1.17Bil, which is flat over Core 2016 total adjusted claims at the midpoint of the range. The company expects Core 2017 adjusted EBITDA guidance to be $4.91-4.97Bil, representing growth of 3% over Core 2016 adjusted EBITDA results at the midpoint of the range.

$ESRX {{ '2017-12-14T15:33:48+0000' | timeago}} • Announcement

$ESRX increased its consolidated 2017 adjusted EPS guidance range to $7.00-7.08, representing growth of 10% over 2016 adjusted EPS at the midpoint of the range. The company narrowed its consolidated 2017 adjusted EBITDA guidance from $7.35-7.47Bil to $7.37-7.45Bil, maintaining the midpoint of the range and up 2% over 2016.

$LLY {{ '2017-12-13T17:55:28+0000' | timeago}} • Announcement

For 2017, $LLY cut down its GAAP EPS outlook and confirmed its non-GAAP EPS and revenue targets. New products and volume are estimated to drive the low-single digit revenue growth in 2018. Eli Lilly expects to make regulatory progress in 2018 on its rheumatoid arthritis drug baricitinib and migraine drug galcanezumab.

$LLY {{ '2017-12-11T21:06:46+0000' | timeago}} • Announcement

$LLY raised its 1Q18 dividend by 8% to $0.5625 per stock. The dividend is payable on March 9, 2018 to shareholders of record as of Feb. 15, 2018.

$LLY {{ '2017-12-11T17:36:13+0000' | timeago}} • Announcement

FDA accepts to review $LLY's Galcanezumab, an injectionable drug for the treatment of migraine. Rivals $NVS and $AMGN already filed their migraine drug with FDA in July 2017, while $TEVA is also expected to join the race. Lilly's pain portfolio also includes Tanezumab, developed in partnership with $PFE, for the treatment of osteoarthritis.

$LLY {{ '2017-12-11T17:32:54+0000' | timeago}} • Announcement

Kimberly Blackwell, a breast cancer researcher, will be joining $LLY's Oncology division as VP of early phase development and immuno-oncology on March 12, 2018. Dr. Blackwell currently serves as professor of medicine and assistant professor of radiation oncology at Duke University Medical Center.

$PMC {{ '2017-12-07T18:06:23+0000' | timeago}} • Announcement

$PMC announced the completion of the acquisition of PharMerica by a newly formed company controlled by KKR with an affiliate of $WBA as a minority investor.

$CVS {{ '2017-12-04T21:29:13+0000' | timeago}} • Announcement

$CVS has agreed to acquire $AET for appox. $207 per share or approx. $69Bil. Including the assumption of $AET debt, the total value of the deal is $77Bil. The transaction is expected to close in the second half of 2018.

$LHCG {{ '2017-12-04T19:56:36+0000' | timeago}} • Announcement

$LHCG and Erlanger Health System have finalized a new JV to enhance home health and community-based services in Chattanooga and southeast Tennessee. The JV includes a Chattanooga facility, which will operate as Erlanger ContinuCare Home Health. $LHCG expects annualized revenue from this JV of approx. $7MM and no material effect to 2017 diluted EPS.

Recent Transcripts

RAD (Rite Aid Corporation)
Wednesday, January 3 2018 - 10:00pm
ENZ (Enzo Biochem Inc.)
Friday, December 8 2017 - 1:30pm
FVE (Five Star Quality Care Inc.)
Thursday, November 9 2017 - 3:00pm
MMS (MAXIMUS, Inc.)
Thursday, November 9 2017 - 2:00pm
GMED (Globus Medical, Inc.)
Wednesday, November 8 2017 - 10:30pm
AMED (Amedisys Inc.)
Wednesday, November 8 2017 - 4:00pm
PRSC (Providence Service Corp.)
Wednesday, November 8 2017 - 1:00pm
KND (Kindred Healthcare Inc.)
Tuesday, November 7 2017 - 2:00pm
LHCG (LHC Group, Inc.)
Monday, November 6 2017 - 4:00pm
CVS (CVS Health Corporation)
Monday, November 6 2017 - 1:30pm
EBS (Emergent BioSolutions, Inc.)
Thursday, November 2 2017 - 9:00pm
FMS (Fresenius Medical Care AG & Co. KGAA)
Thursday, November 2 2017 - 8:30pm
USPH (US Physical Therapy Inc.)
Thursday, November 2 2017 - 2:30pm
BIOS (BioScrip, Inc.)
Thursday, November 2 2017 - 1:00pm
MD (MEDNAX, Inc.)
Wednesday, November 1 2017 - 2:00pm
EVHC (Envision Healthcare Holdings, Inc.)
Wednesday, November 1 2017 - 12:30pm
RDY (Dr. Reddy's Laboratories Ltd.)
Tuesday, October 31 2017 - 1:00pm
CHE (Chemed Corp.)
Friday, October 27 2017 - 2:00pm
TVTY (Tivity Health, Inc.)
Thursday, October 26 2017 - 9:00pm
GSK (GlaxoSmithKline plc)
Wednesday, October 25 2017 - 1:00pm

AlphaGraphics you may like